$769.88
0.55%
NYSE, Jun 06, 10:04 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$769.88
-5.24 0.68% 1M
-56.83 6.87% 6M
-2.12 0.27% YTD
-67.41 8.05% 1Y
+620.67 415.97% 5Y
+691.36 880.49% 10Y
+712.19 1,234.51% 20Y
NYSE, Closing price Fri, Jun 06 2025
+4.20 0.55%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $729.64b
Enterprise Value $764.94b
P/E (TTM) P/E ratio 62.44
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 15.61
P/S ratio (TTM) P/S ratio 14.89
P/B ratio (TTM) P/B ratio 46.28
Dividend yield 0.68%
Last dividend (FY24) $5.20
Revenue growth (TTM) Revenue growth 36.38%
Revenue (TTM) Revenue $49.00b
EBIT (operating result TTM) EBIT $19.72b
Free Cash Flow (TTM) Free Cash Flow $-1.27b
Cash position $3.22b
EPS (TTM) EPS $12.33
P/E forward 36.06
P/S forward 12.23
EV/Sales forward 12.82
Short interest 0.92%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Eli Lilly and Company forecast:

26x Buy
84%
3x Hold
10%
2x Sell
6%

Analyst Opinions

31 Analysts have issued a Eli Lilly and Company forecast:

Buy
84%
Hold
10%
Sell
6%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
49,003 49,003
36% 36%
100%
- Direct Costs 8,969 8,969
26% 26%
18%
40,034 40,034
39% 39%
82%
- Selling and Administrative Expenses 9,110 9,110
20% 20%
19%
- Research and Development Expense 11,202 11,202
14% 14%
23%
21,551 21,551
67% 67%
44%
- Depreciation and Amortization 1,829 1,829
17% 17%
4%
EBIT (Operating Income) EBIT 19,722 19,722
74% 74%
40%
Net Profit 11,106 11,106
81% 81%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Positive
The Motley Fool
37 minutes ago
With the stock market settling in after a volatile period, now is a good time to start looking at some leading growth stocks that have strong potential over the next decade.
Positive
The Motley Fool
one day ago
You don't have to be a billionaire to invest like one -- and reap the rewards. Any of us can look at the moves made by the world's most successful investors and follow those that also fit into our investment strategy.
Positive
Market Watch
3 days ago
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 47,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today